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Background: Patients with manifest atrioventricular accessory pathways (mAPs) have a greater tendency to de-
velop atrial ﬁbrillation (AF) compared with patients with concealed atrioventricular accessory pathways (cAPs).
However, the risk factors of developing AF in patientswith various atrioventricular accessory pathways (APs) are
not clear.
Methods: This retrospective study included 460 symptomatic patients with either cAPs (n = 246) or mAPs
(n = 214) who underwent electrophysiological study and successful radiofrequency catheter ablation of
APs. Clinical and electrophysiological characteristics were compared between cAPs and mAPs and between
AF and non-AF groups with cAPs or mAPs. Independent risk factors of AF were analyzed using multivariate
logistic regression.
Results: AF was more frequent in mAPs group than in cAPs group (23.4% vs 9.8%, p b 0.01). Clinical features
were similar between cAPs and mAPs. Anterograde conduction properties served as the major electrophys-
iological feature of mAPs. Multivariate analysis indicated that mAPs, hypertension, post-ablation P wave
dispersion (Pd), N-terminal proB-type natriuretic peptide (NT-proBNP) and creatinine were independent
risk factors of AF in the complete cohort. Hypertension, post-ablation Pd and high-sensitivity C-reactive
protein (hsCRP) were independent risk factors of AF in cAPs group. Post-ablation Pd, NT-proBNP, creatinine
and shorter effective refractory period of anterograde accessory pathways (AAP ERP) were independent
risk factors of AF in mAPs group.
Conclusions: Results from this study demonstrate that the risk factors of AF are not homogenous between
concealed and manifest APs, which might suggest heterogeneous pathogenesis of AF in these two types
of APs.
© 2015 The Authors. Published by Elsevier Ireland Ltd.This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).terogradeaccessorypathways;
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Atrioventricular accessory pathways (APs) are the abnormal ana-
tomical structures responsible for atrioventricular re-entrant tachycar-
dia (AVRT) [1]. Besides AVRT, atrial ﬁbrillation (AF) is another
common arrhythmias related to APs [2]. Previous studies reported
that patients with APs had a much higher tendency to develop AF
than that in general population [3–6].
APs may exhibit anterograde and (or) retrograde conduction. There
are two types of APs: manifest APs (mAPs) with atrioventricular or
both atrioventricular and ventriculoatrial conduction properties, and
concealed APs (cAPs) with only ventriculoatrial conduction properties.
Previous studies showed that patients with mAPs were more prone to
develop AF than those with cAPs [7,8].
Multiple factors are related to the development of AF in patients
with APs. Previous studies demonstrated that AVRT could spontaneous-
ly degenerate intoAF and surgical or catheter ablation of APs could oftennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics in patients with concealed or manifest APs.





AF 24 (9.8) 50 (23.4) b0.001
Male 150 (61.0) 118 (55.1) 0.206
Age, years 42.7 ± 17.6 42.6 ± 18.2 0.333
Duration of tachycardia, years 7.8 ± 9.2 7.6 ± 10.0 0.860
Presyncope 15 (6.1) 12 (5.6) 0.823
Syncope 6 (2.4) 3 (1.4) 0.643
Hypertension 51 (20.7) 34 (15.9) 0.182
Coronary artery disease 12 (4.9) 19 (8.9) 0.088
Valvular heart disease 1 (0.4) 4 (1.9) 0.189
Diabetes mellitus 15 (6.1) 6 (2.8) 0.091
Chronic kidney disease 176 (71.5) 151 (70.6) 0.816
CHADS2 score 0.4 ± 0.7 0.3 ± 0.6 0.065
CHA2DS2-VASc score 1.1 ± 1.0 1.0 ± 1.0 0.716
Left atrial diameter, mm 31.7 ± 4.3 32.4 ± 4.6 0.052
Left ventricular end-diastolic
diameter, mm
47.3 ± 4.5 47.4 ± 4.0 0.661
Left ventricular ejection fraction, % 66.2 ± 5.6 65.6 ± 5.5 0.413
Pmax, ms 112.6 ± 11.4 113.3 ± 10.2 0.333
Pmin, ms 75.9 ± 9.3 75.8 ± 8.9 0.841
Pd, ms 36.7 ± 9.1 37.5 ± 9.7 0.445
NT-proBNP, pg/mL 49.8 ± 69.0 56.0 ± 76.0 0.229
cTnI, ng/mL 0.033 ± 0.118 0.043 ± 0.172 0.172
Creatinine, μmol/L 63.5 ± 16.9 69.9 ± 64.8 0.092
Uric acid, μmol/L 327.2 ± 84.8 311.9 ± 87.1 0.767
hsCRP, mg/L 3.22 ± 2.03 3.04 ± 2.43 0.459
LDL-c, mmol/L 2.51 ± 0.62 2.53 ± 0.61 0.991
D-dimer, ng/mL 0.16 ± 0.14 0.15 ± 0.14 0.992
Thyrotropin, mIU/L 2.45 ± 1.61 2.36 ± 1.75 0.605
All data in this table were presented as mean ± SD, median ± IQR, or n (%). Pmax,
maximum P wave duration; Pmin, minimum P wave duration; Pd, P wave dispersion;
NT-proBNP, N-terminal-proB-type natriuretic peptide; cTnI, cardiac troponin I; hsCRP,
high-sensitivity C-reactive protein; LDL-c, low density lipoprotein cholesterol.
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one of the mechanisms responsible for the development of AF. On the
other hand, AF might still persist after successful ablation of APs in
some patients, suggesting the existence of AP-independent mecha-
nisms responsible for the pathogenesis of AF [13–15]. Therefore, there
were at least two pathogenesis of AF: AP-dependent and AP-
independent atrial vulnerabilities [16].
This retrospective study was designed to compare the clinical and
electrophysiological characteristics between cAPs and mAPs and be-
tween AF and Non-AF patients with either cAPs or mAPs. This study
also aimed to identify and compare the risk factors responsible for AF
development between patients of these two APs groups.
2. Methods
2.1. Patients
A total of 460 symptomatic patients [268 (58.3%) male, mean age:
42.7 ± 17.9 years old (range 5–91)] with documented AVRT, who
underwent electrophysiological study (EPS) and radiofrequency cathe-
ter ablation (RFCA) from September 2004 to November 2013 in our de-
partment, were included in this study. The existence of APs was
identiﬁed by EPS in all enrolled patients. There were 246 (53.5%) pa-
tients with cAPs and 214 (46.5%) withmAPs. Patients were also divided
into AF group (n=74, 16.1%) and non-AF group (n=386, 83.9%) in the
complete cohort and in patientswith either cAPs ormAPs. Patients in AF
group experienced at least one spontaneous episode of AF recognized
on 12-lead standard electrocardiogram or 24-hour Holter monitoring.
2.2. Pre- and post-procedure management
All patients underwent standard examination procedures. A detailed
medical history, physical examinations, laboratory tests and echocardi-
ography examinations were performed before the EPS procedure. The
laboratory tests included measurement of N-terminal-proB-type natri-
uretic peptide (NT-proBNP), cardiac troponin I (cTnI), creatinine, uric
acid, high-sensitivity C-reactive protein (hsCRP), low density lipopro-
tein–cholesterol (LDL-c), D-dimer and thyrotropin.
After the EPS and AP ablation, a 12-leaded surface electrocardiogram
was recorded immediately. Subsequently, the maximum Pwave duration
(Pmax) and minimum P wave duration (Pmin) were measured, and P
wave dispersion (Pd)was calculatedwith the formula: Pmax− Pmin [17].
2.3. EPS and RFCA
All antiarrhythmic agents were discontinued for at least ﬁve half-
lives prior to the EPS and RFCA. During the procedure, three electrode
catheters were positioned at His bundle region, right ventricular apex
and coronary sinus respectively.
The programmed stimulation protocol, including both atrial and
ventricular incremental pacing and S1S2 extrastimulation, was per-
formed before the RFCA to reveal the anatomical location and electro-
physiological properties of the APs. In this study, the location of APs
was classiﬁed into seven groups around the atrioventricular annulus,
including the anteroseptum, the right free wall, the posteroseptum,
the left posteral wall, the left lateral wall, middle septum and multiple
APs located at different anatomical sites. Several electrophysiological
data weremeasured, including anterograde and retrograde AP effective
refractory period (AAP ERP and RAP ERP), anterograde and retrograde
AP 1:1 conduction (AAP 1:1 conduction and RAP 1:1 conduction) and
cycle lengths of the provoked AVRT (CL).
After completion of the electrophysiological study, the target site of
ablation was identiﬁed. After successful ablation of the APs, another
programmed stimulation protocol was performed to reveal the
electrophysiological properties of atrioventricular node. The electro-
physiological characteristics of atrioventricular node include bothanterograde and retrograde effective refractory period of atrioventricu-
lar node (AAVN ERP and RAVN ERP), anterograde and retrograde atrio-
ventricular nodal 1:1 conduction (AAVN 1:1 conduction and RAVN 1:1)
and dual atrioventricular nodal pathways (DAVNPs), etc.
2.4. Statistical analysis
The statistical computing was performed using the package of SPSS
18.0. Continuous variables with a normal distribution were expressed
as mean ± standard deviation. The intergroup differences were tested
using the t test and the χ2 test. Data with a skewed distribution were
expressed as median ± interquartile range and the intergroup differ-
ences were tested using the Mann–Whitney U test and the χ2 test.
When performing multiple comparisons, the one-way ANOVA with
post hoc test (Scheffe method) was also applied in Tables 3 and 4. Sta-
tistical signiﬁcance was deﬁned as a two-sided p value b 0.05. To
avoid variable selection caused by spurious correlations, only variables
showing an association with AF at the p b 0.10 level in the univariate
analysis were considered as potential risk factors, and then included
into the multivariate regression model. Multivariate logistic regression
analysis was performed in search of independent risk factors of AF.
This analysis was based on a stepwise algorithm, with the p value set
at 0.05 for entering and 0.1 for exclusion. Odds ratio (OR) and 95% con-
ﬁdence intervals (CI) of each independent risk factor for AF in concealed
or manifest APs were reported in Table 5.
3. Results
3.1. Clinical and electrophysiological characteristics of patients with
concealed or manifest APs
AP ablation was successful in all patients. Incidence of AF was signif-
icantly higher in mAPs group than in cAP group. All clinical features
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(Table 1). As for electrophysiological characteristics, the AAP ERP failed
to be measured in 9 cases of mAPs due to either the longer effective re-
fractory period of the atria or the easily provoked AF. The RAP ERP failed
to be measured in 13 cases (6 in cAP group and 7 in mAP group) due to
either the longer effective refractory period of the ventricles or the
easily provoked AF. Besides the anterograde conduction capabilities of
the mAPs, shorter AVN 1:1 conduction was also more often in mAP
group than in cAP group. Moreover, right free wall APs weremore com-
monwhile left lateral APswere less frequent inmAP group compared to
cAPs group (Table 2).
3.2. Clinical and electrophysiological characteristics in concealed or
manifest AP patients with or without AF
As shown in Table 3, AF patients in cAP group (group B) were older,
had higher incidence of hypertension, coronary artery disease, diabetes
mellitus and chronic kidney disease, had larger left atrial diameter and
longer post-ablation Pmax and Pd, and also had higher values of
hsCRP and D-dimer compared with non-AF patients in cAP group
(group A).
Comparedwith non-AF patients inmAP group (group C), AF patients
in mAP group (group D) were older, more frequently male, hyperten-
sive, tended to have a higher incidence of history of coronary artery dis-
ease and chronic kidney disease, had larger left atrial diameter and left
ventricular end-diastolic diameter, had longer Pmax and Pd after abla-
tion and had elevated levels of NT-proBNP, creatinine and D-dimer.
For patientswithout AF history, the clinical characteristicswere sim-
ilar between cAP andmAP groups (group A vs. group C). For individuals
with AF history, patients in cAP group (group B) had higher incidence of
hypertension and diabetesmellitus and larger CHADS2 score than those
in mAP group (group D).
As shown in Table 4, the electrophysiological data, including AAVN
1:1 conduction, AAVN ERP, RAVN 1:1 conduction, RAVN ERP, RAP 1:1
conduction and RAP ERP, were similar between AF and non-AF patients
in cAP group (group B vs. group A). There was also no signiﬁcant differ-
ence in the anatomical sites of the APs, the occurrence of multiple APs
and DAVNPs between the two groups.
Compared with non-AF patients in mAP group (group C), AAP ERP
of AF patients in mAP group (group D) were signiﬁcantly shorter.Table 2
Electrophysiological characteristics in patients with concealed or manifest APs.





AAVN 1:1 conduction, ms 352 ± 22 344 ± 21 0.001
AAVN ERP, ms 265 ± 22 266 ± 17 0.401
RAVN 1:1 conduction, ms 385 ± 42 381 ± 38 0.228
RAVN ERP, ms 318 ± 25 322 ± 26 0.074
AAP 1:1 conduction, ms – 364 ± 20 –
AAP ERP, ms – 308 ± 23 –
RAP 1:1 conduction, ms 298 ± 19 300 ± 20 0.261
RAP ERP, ms 272 ± 18 275 ± 17 0.095
CL, ms 341 ± 41 345 ± 43 0.294
AP numbers, n 1.1 ± 0.3 1.2 ± 0.6 0.278
Location of APs, n (%)
Anteroseptal 4 (1.6) 15 (7.0) 0.004
Right free wall 17 (6.9) 38 (17.8) b0.001
Posteroseptal 29 (11.8) 40 (18.7) 0.039
Left posteral 21 (8.5) 19 (8.9) 0.897
Left lateral 164 (66.7) 85 (39.70) b0.001
Midseptal 1 (0.4) 6 (2.8) 0.087
Multiple 10 (4.1) 11 (5.1) 0.582
DAVNPs, n (%) 12 (4.9) 7 (3.3) 0.388
All data in this tablewere presented asmean± S.D. or n (%). AAVN, anterograde atrioven-
tricular node; ERP, effective refractory period; RAVN, retrograde atrioventricular node;
AAP, anterograde accessory pathway; RAP, retrograde accessory pathway; CL, cycle length
of the provoked atrioventricular reentrant tachycardia; DAVNPs, dual atrioventricular
nodal pathways.Moreover, the location distributions of APs were also statistically differ-
ent. Left lateral APs were prone to be found in group D. Other electro-
physiological parameters (AAVN 1:1 conduction, AAVN ERP, RAVN 1:1
conduction, RAVN ERP, AAP 1:1 conduction, RAP 1:1 conduction,
RAP ERP) were similar between the two groups. There was also no sig-
niﬁcant difference in the occurrence of multiple APs and DAVNPs be-
tween these two groups.3.3. Risk factors for AF in patients with APs
Variables showing association with AF at the level of p b 0.10 in uni-
variate analysis were included into the multivariate logistic regression
model. For the complete cohort, stepwise regression analysis indicated
that mAPs, hypertension, post-ablation Pd, NT-proBNP and creatinine
were independent risk factors of AF in patients with APs (Table 5).
For patients in cAP group, hypertension, post-ablation Pd and hsCRP
were independent risk factors of AF, while post-ablation Pd, NT-proBNP,
creatinine and shorter AAP ERP were independent markers for the de-
velopment of AF in mAPs group (Table 5).4. Discussion
4.1. Main ﬁndings
This study observed that manifest APs had a considerably higher in-
cidence of AF than concealed APs. Anterograde conduction capability
served as the major electrophysiological feature of mAPs. Post-
ablation Pd, NT-proBNP, creatinine and shorter AAP ERP were indepen-
dent risk factors of AF in mAP group while hypertension, Pd and hsCRP
were independent risk factors in cAP group. These different clinical and
electrophysiological properties and risk factors suggested heteroge-
neous pathogenesis of AF between these two types of APs.4.2. Manifest APs had a higher tendency to develop AF
In linewith previous studies [7,18,19], we also observed signiﬁcantly
higher AF incidence in patients with manifest APs compared to
concealed APs (23.4% vs 9.8%, p b 0.01). Multivariate analysis also
showed that manifest APs was an independent risk factor of AF in the
complete cohort. However, the clinical characteristics, including gender,
age, comorbidities, echocardiographic measurements, electrocardio-
gram measurements and AF-associated biomarkers, were similar be-
tween concealed and manifest APs. Besides, the electrophysiological
characteristics of atrioventricular node and retrospective conduction
properties of APs were similar between the two types of APs as well.
These results suggested that the anterograde conduction capability of
APs rather than the retrograde conduction property was the critical de-
terminant of AF.
The reason that manifest APs were associated with increased inci-
dence of AF is not fully understood. Previous literature claimed that an-
atomical structural differences in and near the APs apparently affected
refractoriness and conduction properties of the APs [20]. Branching of
the manifest APs might be the anatomical substrate responsible for
micro-reentry and reﬂection [18]. It is known that the wavetail of the
retrograde impulse propagation to the atrium through manifest APs
could interact with the subsequent anterograde wavefront, initiating
wavebreak and functional reentry in the branching frameworks,
which could then facilitate the initiation and maintenance of AF [21].
Other theory claimed that the manifest APs were associated with in-
creased hemodynamic changes and stretches in atria. The accelerated
atrial remodeling induced by elevated atrial pressure and hypoxia
might be another explanation of the greater tendency of AF in manifest
APs [22]. Further investigations are still needed to clarify the underlying
mechanisms.
Table 3
Clinical characteristics in AF or non-AF patients with concealed or manifest APs.
Clinical characteristics A: non-AF and concealed APs
(n = 222)
B: AF and concealed APs
(n = 24)
C: non-AF and manifest APs
(n = 164)




Male 134 (60.4) 16 (66.7) 81 (49.4) 37 (74.0) ‡
Age, y 41.2 ± 16.8 57.0 ± 18.2* 38.6 ± 17.4 55.9 ± 14.1‡ 19.835 b0.001
Duration of tachycardia, y 7.4 ± 8.9 10.8 ± 11.2 7.2 ± 9.1 9.2 ± 12.5 1.493 0.216
Presyncope 12 (5.4) 3 (12.5) 7 (4.3) 5 (12.0)
Syncope 5 (2.3) 1 (4.2) 2 (1.2) 1 (2.0)
Hypertension 36 (16.2) 15 (62.5)* 20 (12.2) 14 (28.0) †‡
Coronary artery disease 6 (2.7) 6 (25.0)* 7 (4.3) 12 (24.0) ‡
Valvular heart disease 1 (0.5) 0 (0.0) 3 (1.8) 1 (2.0)
Diabetes mellitus 10 (4.5) 5 (20.8)* 5 (3.0) 1 (2.0) †
Chronic kidney disease 153 (68.9) 23 (95.8)* 104 (63.4) 47 (94.0)‡
CHADS2 score 0.3 ± 0.6 1.1 ± 1.1* 0.2 ± 0.5 0.6 ± 0.9†‡ 17.393 b0.001
CHA2DS2-VASc score 0.9 ± 0.8 2.3 ± 1.4* 0.8 ± 0.8 1.7 ± 1.3‡ 29.796 b0.001
Left atrial diameter, mm 31.6 ± 4.4 34.1 ± 5.1* 31.8 ± 4.0 36.4 ± 5.1‡ 15.292 b0.001
Left ventricular end-diastolic diameter, mm 47.2 ± 4.2 49.4 ± 6.2 47.3 ± 3.9 49.1 ± 4.0‡ 3.309 0.020
Left ventricular ejection fraction, % 66.2 ± 5.4 65.8 ± 7.2 65.8 ± 5.4 64.7 ± 7.1 1.615 0.185
Pmax, ms 111.5 ± 10.8 122.1 ± 11.8* 111.2 ± 9.7 120.4 ± 8.1‡ 18.227 b0.001
Pmin, ms 75.8 ± 9.2 76.7 ± 10.1 75.7 ± 9.1 76.0 ± 8.3 0.079 0.972
Pd, ms 35.7 ± 8.4 45.4 ± 11.0* 35.4 ± 8.7 44.4 ± 9.7‡ 22.267 b0.001
NT-proBNP, pg/ml 46.5 ± 56.0 132.8 ± 311.0 51.2 ± 51.0 124.5 ± 678.0‡ 10.386 b0.001
cTnI, ng/ml 0.031 ± 0.119 0.055 ± 0.114 0.032 ± 0.182 0.082 ± 0.128 1.894 0.130
Creatinine, μmol/L 63.0 ± 17.1 69.0 ± 14.7 62.2 ± 18.5 95.2 ± 127.6‡ 7.760 b0.001
Uric acid, μmol/L 324.0 ± 83.5 356.8 ± 92.7 309.8 ± 86.2 318.8 ± 90.7 2.407 0.067
hsCRP, mg/ L 3.32 ± 1.96 5.06 ± 2.80* 3.36 ± 2.46 4.39 ± 4.29 5.627 0.001
LDL-c, mmol/ L 2.52 ± 0.64 2.42 ± 0.42 2.54 ± 0.62 2.50 ± 0.58 0.249 0.862
D-dimer, ng/ml 0.15 ± 0.12 0.24 ± 0.22* 0.13 ± 0.11 0.22 ± 0.19‡ 9.405 b0.001
Thyrotropin, mIU/L 2.49 ± 1.65 2.02 ± 1.14 2.38 ± 1.89 2.31 ± 1.19 0.692 0.557
All data in this tablewere presented asmean± SD,median± IQR, or n (%). p b 0.05, * vs A, † vs B, ‡ vs C. ANOVA, analysis of variance; Pmax,maximumPwave duration; Pmin,minimumP
wave duration; Pd, P wave dispersion; NT-proBNP, N-terminal-proB-type natriuretic peptide; cTnI, cardiac troponin I; hsCRP, high-sensitivity C-reactive protein; LDL-c, low density lipo-
protein cholesterol.
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manifest APs
Although with some inconsistencies, the majority of previous
studies observed that AAP ERP appeared shorter in AF group than in
the control group for patients with manifest APs [8,23–25]. Soylu et al.
[23] reported that, both AAP ERP and RAP ERP were shorter in AF
group. Fujimura et al. [24] reported that AAP ERP was shorter in AF
group while RAP ERP remained similar between AF group and the con-
trol. Our study came up with the similar result as Fujimura's report.Table 4
Electrophysiological characteristics in AF or non-AF patients with concealed or manifest APs.
Electrophysiological characteristics A: non-AF and concealed APs
(n = 222)
B: AF and conceale
(n = 24)
AAVN 1:1 conduction, ms 351 ± 21 357 ± 30
AAVN ERP, ms 264 ± 21 269 ± 26
RAVN 1:1 conduction, ms 383 ± 39 404 ± 61
RAVN ERP, ms 318 ± 25 322 ± 27
AAP 1:1 conduction, ms – –
AAP ERP, ms – –
RAP 1:1 conduction, ms 298 ± 19 300 ± 25
RAP ERP, ms 272 ± 18 276 ± 23
CL, ms 342 ± 40 328 ± 40
AP numbers, n 1.0 ± 0.0 1.0 ± 0.0
Location of APs, n (%)
Anteroseptal 4 (1.8) 0 (0.0)
Right free-wall 16 (7.2) 1 (4.2)
Posteroseptal 26 (11.7) 3 (12.5)
Left posteral 19 (8.6) 2 (8.3)
Left lateral 147 (66.2) 17 (70.8)
Midseptal 0 (0.0) 1 (4.2)
Multiple 10 (4.5) 0 (0.0)
DAVNPs, n (%) 12 (5.4) 0 (0.0)
All data in this table were presented asmean± S.D. or n (%). p b 0.05, * vs A, † vs B, ‡ vs C. ANOV
period; RAVN, retrograde atrioventricular node; AAP, anterograde accessory pathway; RAP, re
tachycardia; DAVNPs, dual atrioventricular nodal pathways.Moreover, according to multivariate regression analysis, shorter AAP
ERP served as an independent risk factor of AF in manifest APs.
It still remains uncertain how the shortened AAP ERP enhances the
propensity of AF in manifest APs. One mechanism is that shorter AAP
ERP allows faster ventricular responses during atrial tachycardia or
other types of supraventricular tachycardia. Another possible mecha-
nism is that shorter AAP ERP could facilitate micro-reentry within
the branching frameworks of the manifest APs. In addition, shortened
AAP ERP might be correlated with severe cardiac sympathetic dysfunc-
tion, which is associated with the occurrence of AF in patients withd APs C: non-AF and manifest APs
(n = 164)




345 ± 21 342 ± 21 4.846 0.002
267 ± 17 264 ± 16 0.947 0.418
382 ± 38 378 ± 39 2.440 0.064
322 ± 26 323 ± 29 1.248 0.292
365 ± 21 360 ± 17
314 ± 19 286 ± 18‡
300 ± 20 299 ± 21 0.524 0.666
275 ± 17 275 ± 17 1.351 0.257
344 ± 43 347 ± 40 1.247 0.292
1.1 ± 0.3 1.2 ± 0.6 2.117 0.097
13 (7.9) * 2 (4.0)
34 (20.7)* 4 (8.0)‡
31 (18.9)* 9 (18.0)
16 (9.8) 3 (6.0)
56 (34.1)* 29 (58.0)‡
6 (3.7)* 0 (0)
8 (4.9) 3 (6.0)
3 (1.8) 4 (8.0)
A, analysis of variance; AAVN, anterograde atrioventricular node; ERP, effective refractory
trograde accessory pathway; CL, cycle length of the provoked atrioventricular reentrant
Table 5
Independent risk factors of AF in patients with APs, concealed APs and manifest APs.
Clinical/electrophysiological parameters OR 95% CI p value
APs (complete cohort)
mAPs 3.340 1.781–6.264 b0.001
Hypertension 3.006 1.546–5.845 0.001
Post-ablation Pd 1.097 1.062–1.132 b0.001
NT-proBNP 1.001 1.000–1.001 0.018
Creatinine 1.026 1.010–1.043 0.001
Concealed APs
Hypertension 7.478 2.798–19.983 b0.001
Post-ablation Pd 1.090 1.034–1.149 0.001
hsCRP 1.233 1.017–1.496 0.033
Manifest APs
Post-ablation Pd 1.088 1.026–1.153 0.005
NT-proBNP 1.003 1.000–1.006 0.020
Creatinine 1.057 1.022–1.093 0.001
AAP ERP 0.970 0.947–0.994 0.015
OR, odds ratio; CI: conﬁdence interval; AAP ERP: effective refractory period of anterograde
accessory pathways.
73M. Chen et al. / IJC Heart & Vasculature 7 (2015) 69–75WPW syndrome [26]. All above-mentioned mechanisms can lead to in-
appropriate atrial stretch and hypoxia, therefore, increase the AP-
dependent atrial vulnerability and contribute to the genesis and sus-
taining of AF.
In both concealed and manifest APs, the RAP ERP showed no
difference between AF and Non-AF groups in our study. Thus, the anter-
ograde rather than the retrograde conduction properties of APs took
a crucial role in pathogenesis of AF. These results suggested that the
AP-dependent atrial vulnerability contributed more in manifest APs
than in concealed APs.
4.4. Hypertension increased the AP-independent atrial vulnerability
Although most patients with APs were relatively young and did not
have structural heart diseases, some individuals do developed comor-
bidities with aging, such as hypertension, coronary artery disease, val-
vular heart disease and diabetes mellitus. These comorbidities, which
were proved to be risk factors of AF in general population,might also in-
crease intrinsic atrial vulnerability in patients with APs [27]. In the pres-
ent study, the incidence of hypertension, coronary artery disease,
valvular heart disease and diabetes mellitus in APs were 18.5%, 6.7%,
1.1% and 4.6%, respectively. For both concealed andmanifest APs, the in-
cidences of hypertension and coronary artery disease were higher in AF
group. AF patients with concealed APs tended to have higher incidence
of diabetes mellitus as well. Previous literatures demonstrated that hy-
pertension was an independent risk predictor for AF in general popula-
tion without APs [28,29]. In our study, multivariate analysis showed
that hypertensionwas an independent risk factor for AF in the complete
cohort (OR = 3.006) and in concealed AP group (OR = 7.478). These
results suggested that hypertension, as well as coronary artery
disease and diabetes mellitus, might increase the intrinsic and AP-
independent atrial vulnerability in patients with APs, especially in
concealed APs. Hypertension served as the major risk factor of AF in pa-
tients with concealed APs.
4.5. P wave dispersion reﬂected the intrinsic atrial muscle vulnerability
Atrial electrophysiological abnormalities, especially atrial conduc-
tion delays were observed in patients with APs, even if they had no pre-
vious history of AF [30]. These abnormalities were thought to be
critically associated with the vulnerability to AF. Atrial conduction de-
lays and dispersion can be evaluated by not only the invasive EPS but
also the noninvasive, 12-lead surface ECG. P-wave dispersion (Pd) is de-
ﬁned as the difference between themaximum Pwave duration (Pmax)
and the minimum P wave duration (Pmin) recorded from multiple dif-
ferent ECG leads [17]. Signiﬁcant correlations have been shown be-
tween Pmax and the longest duration of the right atrial electrograms,the maximal number of their fragmented deﬂections and the repetitive
atrial ﬁring zone [31]. Pd could also be attributed to an underlying het-
erogeneity of atrial conduction [32,33].
Formanifest APs,measuring the Pwaveduration is a difﬁcult job due
to the ventricular preexcitation and the existence of deltawave. Besides,
the impulse could propagate retrogradely from ventricle to atrium
through either concealed or manifest APs, resulting in slower conduc-
tion velocity of the next sinus impulse. Therefore, P wave duration
should be measured after the ablation of APs. Previous study reported
that Pmax and Pd became signiﬁcantly longer in patients with AF histo-
ry even when left atrial diameter and left ventricular ejection fraction
were similar between AF and the control groups [23]. It suggested that
Pmax and Pd might be more sensitive than left atrial diameter in
reﬂecting atrial remodeling during AF genesis. In our study, Pmax and
Pdwere signiﬁcantly larger in AF group than in non-AF group. Andmul-
tivariate analysis also showed that Pd was an independent risk factor of
AF in both concealed and manifest APs. These results indicated that the
atrial conducting delays, inhomogeneous and discontinuous propaga-
tion of sinus impulses and increased atrial muscle intrinsic vulnerability
played a critical role in the pathogenesis of AF.4.6. AF-associated biomarkers in patients with APs
Growing evidences show that inﬂammation might be associated
with the pathogenesis of AF [34]. CRP, an acute phase protein produced
by the liver, is one of inﬂammatory biomarkers associated with AF gen-
esis [35]. The continuous development of more sensitive CRP methods
(high-sensitivity CRP, hsCRP) has made it possible to detect and mea-
sure CRP level in almost all individuals. Although some inconsistencies
exist, themajority of studies reported elevated CRP levels to be an inde-
pendent risk factors for AF in general population [36,37]. In our study,
the level of hsCRP was signiﬁcant higher in AF group and hsCRP was
an independent risk factor of AF in concealed APs. These results sug-
gested that the increased inﬂammatory state and AP-independent atrial
vulnerabilitymight play important roles in the development of AF in pa-
tients with APs.
Creatinine is accepted as a useful index of renal function. The preva-
lence of AF was higher in patients of chronic kidney disease compared
with general population [38–40]. In general population, the AF preva-
lence increased with increasing creatinine and decreasing GFR values
[41,42]. In the present study, the creatinine value was elevated in AF
group of patients with manifest APs. Multivariate regression also indi-
cated that creatinine was an independent risk factor of AF in manifest
APs. Thus, renal dysfunction, acting as one part of AP-independent atrial
vulnerability, plays an important role in the pathogenesis of AF in pa-
tients with manifest APs.
N-terminal pro-B-type natriuretic peptide (NT-proBNP), largely pro-
duced by the ventricles, is considered as a biomarker of cardiac failure.
However, physiological studies also observed increased BNP production
in the atria of individuals with AF [43,44]. It was reported that NT-
proBNP level was signiﬁcantly higher in patients with AF compared
with controls in sinus rhythm [45]. Previous studies demonstrated
that the higher NT-proBNP value could predict an increased risk of de-
velopment of AF in community-based population, even after adjust-
ment for other known risk factors of AF [46,47]. However, there was
limited information on the role of NT-proBNP in APs population. In
our study, the level of NT-proBNP was signiﬁcantly higher in AF group
than in non-AF group for manifest APs patients. Moreover, NT-proBNP
was an independent risk factor of AF in the complete cohort and inman-
ifest AP patients. The elevated NT-proBNP values might be attributed to
alteration in ventricular and atrial ﬁlling patterns. Atrial vulnerability
would increase with the electrical conduction through the APs, the
loss ofmechanical atrial synchrony, the calciumoverload andmyocardi-
al ischemia, leading to the appearance and maintenance of AF in pa-
tients with APs.
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As mentioned above, the AP-independent and AP-dependent atrial
vulnerabilities were hypothesized as two possible mechanisms of AF
[16]. Results from this study suggested heterogeneous mechanisms of
AF for concealed and manifest APs.
For concealed APs, plenty of clinical differences but no electrophys-
iological difference were found between AF and non-AF groups, sug-
gesting that the intrinsic, atrium-inherent and AP-independent atrial
vulnerability played a critical role in AF genesis.
Formanifest APs, however, both clinical and electrophysiological dif-
ferences were reported between AF and non-AF groups, indicating that
not only AP-independent atrial vulnerability but also AP-dependent
atrial vulnerability played important roles in the development of AF.
Moreover, the incidences of hypertension and diabetes mellitus,
which were considered as important contributors of intrinsic and AP-
independent atrial vulnerability, were even lower in AF patients with
manifest APs compared to AF patients with concealed APs. Considering
the higher AF incidence in patients with manifest APs, above results
suggested that the AP-dependent atrial vulnerability might contribute
more for the AF genesis in patients with manifest APs.5. Limitations
Limitations of this study need to be addressed. First, the nature of the
design of this retrospective study can only demonstrate an association
rather than a causal relationship between all these clinical and electro-
physiological factors and AF development in AP patients. A prospective
study aswell as a follow-up study to estimate the risk factors of AF after
AP ablation is still required. Second, Svendsen et al. [48] reported a sur-
vey of a large number of AP patients who were either symptomatic or
asymptomatic and who had ablation as well as those who did not
have ablation. In the present study, however, the patients were all
symptomatic and selected to have an electrophysiological study and ab-
lation. Therefore, it is difﬁcult to identify risk factors of AF in those who
were asymptomatic and who were symptomatic but did not have an
electrophysiological study and ablation. Further studies on this issue
are required. Third, the electrophysiological data of atrioventricular
nodesweremeasured after the ablation of APs.Weare not surewhether
the ablation of APswould change the conduction properties of atrioven-
tricular nodes. It is worth noting that the electrophysiological data of
atrioventricular nodes were difﬁcult to acquire before AP ablation in a
part of patients due to the provocation of AVRT or AF.6. Conclusions
This study evaluated the different clinical and electrophysiological
characteristics between concealed and manifest APs and between AF
and non-AF groups in each type of APs. Results from this study demon-
strate that the risk factors of AF are not homogenous between concealed
and manifest APs, which might suggest heterogeneous pathogenesis of
AF in these two types of APs.Funding
This work was supported by the National Natural Science Foundation
of China [No. 81270258, No. 81070154] and the Shanghai City Committee
of Science and Technology Research Projects [No. 11JC1408200,
No. 12411951900].Conﬂict of interest
None declared.References
[1] Deal BJ, Keane JF, Gillette PC PC, Garson Jr A. Wolff–Parkinson–White syndrome and
supraventricular tachycardia during infancy: management and follow-up. J Am Coll
Cardiol 1985;5:130–5.
[2] Brembilla-Perrot B, Popescu I, Huttin O, Zinzius PY, Muresan L, Jarmouni S, et al. Risk
of atrial ﬁbrillation according to the initial presentation of a preexcitation syndrome.
Int J Cardiol 2012;157:359–63.
[3] Sharma AD, Klein GJ, Guiraudon GM, Milstein S. Atrial ﬁbrillation in patients with
Wolff–Parkinson–White syndrome: incidence after surgical ablation of the accesso-
ry pathway. Circulation 1985;72:161–9.
[4] Campbell RW, Smith RA, Gallagher JJ, Pritchett EL, Wallace AG. Atrial ﬁbrillation in
the preexcitation syndrome. Am J Cardiol 1977;40:514–20.
[5] Wellens HJ, Brugada P, Roy D, Weiss J, Bär FW. Effect of isoproterenol on the anter-
ograde refractory period of the accessory pathway in patients with the Wolff–
Parkinson–White syndrome. Am J Cardiol 1982;50:180–4.
[6] Borregaard R, Lukac P, Gerdes C, Gerdes C, Møller D, Mortensen PT, Pedersen L, et al.
Radiofrequency ablation of accessory pathways in patients with the Wolff–
Parkinson–White syndrome: the long-term mortality and risk of atrial ﬁbrillation.
Europace 2014. http://dx.doi.org/10.1093/europace/euu176.
[7] Della Bella P, Brugada P, Talajic M, Lemery R, Torner P, Lezaun R, et al. Atrial ﬁbrilla-
tion in patients with an accessory pathway: importance of the conduction properties
of the accessory pathway. J Am Coll Cardiol 1991;17:1352–6.
[8] Chen SA, Chiang CE, Tai CT, Lee SH, Chiou CW, Ueng KC, et al. Longitudinal clinical
and electrophysiological assessment of patients with symptomatic Wolff–
Parkinson–White syndrome and atrioventricular node reentrant tachycardia. Circu-
lation 1996;93:2023–32.
[9] Weiss R, Knight BP, Bahu M, Zivin A, Souza J, Goyal R, et al. Long-term follow-up
after radiofrequency ablation of paroxysmal supraventricular tachycardia in patients
with tachycardia-induced atrial ﬁbrillation. Am J Cardiol 1997;80:1609–10.
[10] Zhang Y, Wang L. Atrial vulnerability is a major mechanism of paroxysmal atrial ﬁ-
brillation in patients with Wolff–Parkinson–White syndrome. Med Hypotheses
2006;67:1345–7.
[11] Peinado R, Merino JL, Gnoatto M, Arias MA. Atrial ﬁbrillation triggered by
postinfarction ventricular premature beats in a patient with Wolff–Parkinson–
White syndrome. Europace 2005;7:221–4.
[12] Pappone C, Vicedomini G, Manguso F, Saviano M, Baldi M, Pappone A, et al. Wolff–
Parkinson–White syndrome in the era of catheter ablation: insights from a registry
study of 2169 patients. Circulation 2014;130:811–9.
[13] Oddsson H, Edvardsson N,Walfridsson H. Episodes of atrial ﬁbrillation and atrial vul-
nerability after successful radiofrequency catheter ablation in patients with Wolff–
Parkinson–White syndrome. Europace 2002;4:201–6.
[14] Dagres N, Clague JR, Lottkamp H, Hindricks G, Breithardt G, Borggrefe M. Impact of
radiofrequency catheter ablation of accessory pathways on the frequency of atrial ﬁ-
brillation during long-term follow-up; high recurrence rate of atrial ﬁbrillation in
patients older than 50 years of age. Eur Heart J 2001;22:423–7.
[15] Derejko P, Szumowski LJ, Sanders P, KrupaW, Bodalski R, Orczykowski M, et al. Atri-
al ﬁbrillation in patients withWolff–Parkinson–White syndrome: role of pulmonary
veins. J Cardiovasc Electrophysiol 2012;23:280–6.
[16] Hamada T, Hiraki T, Ikeda H, Kubara I, Yoshida T, OhgaM, et al. Mechanisms for atrial
ﬁbrillation in patients with Wolff–Parkinson–White syndrome. J Cardiovasc
Electrophysiol 2002;13:223–9.
[17] Aytemir K, Ozer N, Atalar E, Sade E, Aksöyek S, Ovünç K, et al. P wave dispersion on
12-lead electrocardiography in patients with paroxysmal atrial ﬁbrillation. Pacing
Clin Electrophysiol 2000;23:1109–12.
[18] Schwieler JH, Zlochiver S, Pandit SV, Berenfeld O, Jalife J, Bergfeldt L. Reentry in an
accessory atrioventricular pathway as a trigger for atrial ﬁbrillation initiation in
manifest Wolff–Parkinson–White syndrome: a matter of reﬂection? Heart Rhythm
2008;5:1238–47.
[19] Ma L, Li Y, Wang Y, Wang X, Kong J, Wang L. Relationship between accessory path-
way location and occurrence of atrial ﬁbrillation in patients with atrioventricular re-
entrant tachycardia. Exp Clin Cardiol 2004;9:196–9.
[20] Inoue H, Zipes DP. Conduction over an isthmus of atrial myocardium in vivo: a
possible model of Wolff–Parkinson–White syndrome. Circulation 1987;76:
637–47.
[21] Lesh MD, Van Hare GF, Schamp DJ, Chien W, Lee MA, Grifﬁn JC, et al. Curative
percutaneous catheter ablation using radiofrequency energy for accessory path-
ways in all locations: results in 100 consecutive patients. J Am Coll Cardiol 1992;
19:1303–9.
[22] Feng XF, Wang QS, Sun J, Zhang PP, Wang J, Wang YP, et al. Pulmonary vein antrum
isolation of pre-excited atrial ﬁbrillation. Chin Med J (Engl) 2013;126:2613–9.
[23] Soylu M, Demir AD, Ozdemir O, Soylu O, Topaloğlu S, Korkmaz S, et al. Increased P
wave dispersion after the radiofrequency catheter ablation in overt pre-excitation
patients: the role of atrial vulnerability. Int J Cardiol 2004;95:167–70.
[24] Fujimura O, Klein GJ, Yee R, Sharma AD. Mode of onset of atrial ﬁbrillation in the
Wolff–Parkinson–White syndrome: how important is the accessory pathway? J
Am Coll Cardiol 1990;15:1082–6.
[25] AsanoY,KanekoK,MatsumotoK, Saito J, YamamotoT,Dohi Y.Atrialﬁbrillation andatrial
vulnerability in the Wolff–Parkinson–White syndrome. Jpn Circ J 1991;55:287–96.
[26] Akutsu Y, Kaneko K, Kodama Y, Li HL, Asano T, Suyama J, et al. Usefulness of se-
vere cardiac sympathetic dysfunction to predict the occurrence of rapid atrial
ﬁbrillation in patients with Wolff–Parkinson–White syndrome. Am J Cardiol
2013;112:688–93.
[27] Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent
risk factors for atrial ﬁbrillation in a population-based cohort. The Framingham
Heart Study. JAMA 1994;271:840–4.
75M. Chen et al. / IJC Heart & Vasculature 7 (2015) 69–75[28] KannelWB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic
atrial ﬁbrillation: the Framingham Study. N Engl J Med 1982;306:1018–22.
[29] Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atri-
al ﬁbrillation: incidence, risk factors, and prognosis in theManitoba follow-up study.
Am J Med 1995;98:476–84.
[30] Sakabe K, Fukuda N, Nada T, et al. Atrial electrophysiologic abnormalities in patients
with Wolff–Parkinson–White syndrome but without paroxysmal atrial ﬁbrillation.
Clin Cardiol 2004;27:396–400.
[31] Centurión OA, Shimizu A, Isomoto S, et al. Inﬂuence of advancing age on fractionated
right atrial endocardial electrograms. Am J Cardiol 2005;96:239–42.
[32] Ramanna H, Hauer RN, Wittkampf FH, de Bakker JM, Wever EF, Elvan A, et al. Iden-
tiﬁcation of the substrate of atrial vulnerability in patients with idiopathic atrial ﬁ-
brillation. Circulation 2000;101:995–1001.
[33] Cui QQ, ZhangW,Wang H, Sun X, Wang R, Yang HY, et al. Assessment of atrial elec-
tromechanical coupling and inﬂuential factors in nonrheumatic paroxysmal atrial ﬁ-
brillation. Clin Cardiol 2008;31:74–8.
[34] Issac TT, Dokainish H, Lakkis NM. Role of inﬂammation in initiation and perpetuation
of atrial ﬁbrillation: a systematic review of the published data. J Am Coll Cardiol
2007;50:2021–8.
[35] Schnabel RB, LarsonMG, Yamamoto JF, Kathiresan S, Rong J, Levy D, et al. Relation of
multiple inﬂammatory biomarkers to incident atrial ﬁbrillation. Am J Cardiol 2009;
104:92–6.
[36] Casaclang-Verzosa G, Barnes ME, Blume G, Seward JB, Gersh BJ, Cha SS, et al. C-
reactive protein, left atrial volume, and atrial ﬁbrillation: a prospective study in
high-risk elderly. Echocardiography 2010;27:394–9.
[37] Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, et al.
Does elevated C-reactive protein increase atrial ﬁbrillation risk? A Mendelian ran-
domization of 47,000 individuals from the general population. J Am Coll Cardiol
2010;56:789–95.
[38] Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi
KE, et al. Prevalence of atrial ﬁbrillation and its predictors in nondialysis patients
with chronic kidney disease. Clin J Am Soc Nephrol 2010;5:173–81.[39] Deo R, Katz R, Kestenbaum B, Fried L, Sarnak MJ, Psaty BM, et al. Impaired kidney
function and atrial ﬁbrillation in elderly subjects. J Card Fail 2010;16:55–60.
[40] Genovesi S, Pogliani D, Faini A, Valsecchi MG, Riva A, Stefani F, et al. Prevalence of
atrial ﬁbrillation and associated factors in a population of long-term hemodialysis
patients. Am J Kidney Dis 2005;46:897–902.
[41] Iguchi Y, Kimura K, Kobayashi K, Aoki J, Terasawa Y, Sakai K, et al. Relation of atrial
ﬁbrillation to glomerular ﬁltration rate. Am J Cardiol 2008;102:1056–9.
[42] McManus DD, Corteville DC, Shlipak MG, Whooley MA, Ix JH. Relation of kidney
function and albuminuria with atrial ﬁbrillation (from the Heart and Soul Study).
Am J Cardiol 2009;104:1551–5.
[43] Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic
peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natri-
uretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin
Invest 1991;87:1402–12.
[44] Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natri-
uretic polypeptide in patients with atrial ﬁbrillation. J Card Fail 2000;6:92–6.
[45] Shelton RJ, Clark AL, Goode K, Rigby AS, Cleland JG. The diagnostic utility of N-
terminal pro-B-type natriuretic peptide for the detection of major structural heart
disease in patients with atrial ﬁbrillation. Eur Heart J 2006;27:2353–61.
[46] Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, et al.
N-terminal pro-B-type natriuretic peptide is a major predictor of the development
of atrial ﬁbrillation: the Cardiovascular Health Study. Circulation 2009;120:1768–74.
[47] Patton KK, Heckbert SR, Alonso A, Bahrami H, Lima JA, Burke G, et al. N-terminal pro-
B-type natriuretic peptide as a predictor of incident atrial ﬁbrillation in the Multi-
Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart 2013;
99:1832–6.
[48] Svendsen JH, Dagres N, Dobreanu D, Bongiorni MG, Marinskis G, Blomström-
Lundqvist C, et al. Current strategy for treatment of patients with Wolff–
Parkinson–White syndrome and asymptomatic preexcitation in Europe: European
Heart Rhythm Association survey. Europace 2013;15:750–3.
